Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index; 12 of the 16 sources its claims cite were checked for support.
Abstract
BACKGROUND: Vaccines are needed to prevent coronavirus disease 2019 (Covid-19) and to protect persons who are at high risk for complications. The mRNA-1273 vaccine is a lipid nanoparticle-encapsulated mRNA-based vaccine that encodes the prefusion stabilized full-length spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes Covid-19. METHODS: This phase 3 randomized, observer-blinded, placebo-controlled trial was conducted at 99 centers across the United States. Persons at high risk for SARS-CoV-2 infection or its complications were randomly assigned in a 1:1 ratio to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart. The primary end point was prevention of Covid-19 illness with onset at least 14 days after the second injection in participants who had not previously been infected with SARS-CoV-2. RESULTS: The trial enrolled 30,420 volunteers who were randomly assigned in a 1:1 ratio to receive either vaccine or placebo (15,210 participants in each group). More than 96% of participants received both injections, and 2.2% had evidence (serologic, virologic, or both) of SARS-CoV-2 infection at baseline. Symptomatic Covid-19 illness was confirmed in 185 participants in the placebo group (56.5 per 1000 person-years; 95% confidence interval [CI], 48.7 to 65.3) and in 11 participants in the mRNA-1273 group (3.3 per 1000 person-years; 95% CI, 1.7 to 6.0); vaccine efficacy was 94.1% (95% CI, 89.3 to 96.8%; P<0.001). Efficacy was similar across key secondary analyses, including assessment 14 days after the first dose, analyses that included participants who had evidence of SARS-CoV-2 infection at baseline, and analyses in participants 65 years of age or older. Severe Covid-19 occurred in 30 participants, with one fatality; all 30 were in the placebo group. Moderate, transient reactogenicity after vaccination occurred more frequently in the mRNA-1273 group. Serious adverse events were rare, and the incidence was similar in the two groups. CONCLUSIONS: The mRNA-1273 vaccine showed 94.1% efficacy at preventing Covid-19 illness, including severe disease. Aside from transient local and systemic reactions, no safety concerns were identified. (Funded by the Biomedical Advanced Research and Development Authority and the National Institute of Allergy and Infectious Diseases; COVE ClinicalTrials.gov number, NCT04470427.).
Overview
CoChat Summary
TL;DR
In a phase 3 U.S. trial, mRNA-1273 (100 μg given as two doses 28 days apart) prevented symptomatic Covid-19 with 94.1% efficacy and showed no safety concerns beyond transient reactogenicity. Severe Covid-19 occurred in 30 participants, all in the placebo group.
Key findings
- Among 30,420 randomized participants (15,210 per group), the primary per-protocol analysis found symptomatic Covid-19 in 11 mRNA-1273 recipients vs. 185 placebo recipients (3.3 vs. 56.5 per 1000 person-years), for vaccine efficacy of 94.1% (95% CI, 89.3 to 96.8; P<0.001).
- Severe Covid-19 occurred in 30 participants, all in the placebo group (vaccine efficacy 100%; 95% CI could not be estimated to 1.0), including one Covid-19–related death.
- Solicited local adverse events were more frequent with mRNA-1273 after dose 1 (84.2% vs. 19.8%) and dose 2 (88.6% vs. 18.8%); solicited systemic events were also more frequent after dose 1 (54.9% vs. 42.2%) and dose 2 (79.4% vs. 36.5%). Serious adverse events were similar (0.6% in both groups).
- Efficacy was similar across subgroups, including 95.6% among participants 18 to <65 years, 86.4% among those ≥65 years, and 97.5% in communities of color.
Methods
- Phase 3 randomized, observer-blinded, placebo-controlled trial conducted at 99 U.S. centers; adults at high risk for SARS-CoV-2 infection or severe Covid-19 were assigned 1:1 to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart.
- The primary end point was prevention of symptomatic Covid-19 with onset at least 14 days after the second injection in per-protocol participants who were seronegative at baseline; cases were adjudicated, and vaccine efficacy was defined as 1 minus the hazard ratio (mRNA-1273 vs. placebo) using a stratified Cox proportional hazards model.
- Safety was assessed in all participants who received at least one injection, including solicited local and systemic adverse events for 7 days after each injection, unsolicited adverse events for 28 days, and serious/medically attended events through day 759.
Limitations
- Stated: short duration of safety and efficacy follow-up (median 64 days after the second dose; 2-year follow-up planned); no identified correlate of protection; insufficient data to assess asymptomatic infection; limited cases in older adults, racial/ethnic minorities, and previously infected persons; pregnant women and children were excluded.
- Stated: the trial was not designed to evaluate single-dose efficacy; rare adverse events are hard to detect given sample size; long-term risk of enhanced respiratory disease after exposure remains unknown.
- Evident: the primary analysis reflects only short-term follow-up, so durability of protection is unknown; subgroup estimates have wide confidence intervals (e.g., ≥65 years: 86.4%, 95% CI 61.4 to 95.2).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 0 Not valid · 3 Not checked · 79 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“The efficacy of mRNA-1273 is in line with that of the recently reported BNT162b2 mRNA vaccine. 16”
What the sources say
- Supportedcites [16] 16. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 Covid-19 vaccine. N Engl J Med 2020; 383: 2603-15. source
The Abstract Results report that BNT162b2 was 95% effective in preventing Covid-19, and the Discussion likewise describes 95% efficacy after two doses. The comparison with mRNA-1273 is the citing authors’ own framing; this source supplies the BNT162b2 efficacy result. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The reactogenicity associated with immunization with mRNA-1273 in this trial is similar to that in the phase 1 data reported previously. 1,4”
What the sources say
- Supportedcites [1] 1. Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA vaccine against SARS-CoV-2 - preliminary report. N Engl J Med 2020; 383: 1920-31. source
The Methods identify this as a phase 1 trial of mRNA-1273 that evaluated reactogenicity. The Results (Vaccine Safety; page unavailable) report its reactogenicity findings, so it supports the citation’s reference to previously reported phase 1 data. (LLM, conf=0.88)
- Supportedcites [4] 4. Anderson EJ, Rouphael NG, Widge AT, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med 2020; 383: 2427-38. source
The Discussion states that the authors observed no systematic differences in reactogenicity between the older participants in this study and younger mRNA-1273 recipients reported previously. It cautions that the small groups do not permit meaningful formal statistical comparisons, but the citing sentence makes only a qualitative comparison. (LLM, conf=0.93)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the overall population, the incidence of treatment-related severe adverse events was higher in the mRNA-1273 group (71 participants [0.5%]) than in the placebo group (28 participants [0.2%]) (Tables S8 and S15).”
plainstates an associationn = 71- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Adverse events that were deemed by the trial team to be related to the vaccine or placebo were reported among 4.5% of participants in the placebo group and 8.2% in the mRNA-1273 group.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The relative incidence of these adverse events according to vaccine group was not affected by age.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
35 more claims
Create a free account to see all 88 claims and every source verdict.
- It may state two separate claims as one. 39
- Probably not a substantial claim. 21
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [44]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [31]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Currently licensed vaccines have shown efficacies of up to 95% in preventing laboratory-confirmed infection over the first few months after vaccination61–63”
From Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection (2021) · cites this paper as [62]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The two mRNA vaccines approved to date show efficacy even after only one dose, when non-NAbs and moderate T helper 1 cell responses are detectable, but almost no NAbs.”
From Immunological mechanisms of vaccine-induced protection against COVID-19 in humans (2021) · cites this paper as [82]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Robust CD4+ and CD8+ T cell memory is induced after COVID-19,22,39, 40, 41 and multiple COVID-19 vaccines elicit CD4+ and CD8+ T cell responses.26,42, 43, 44, 45”
From Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals (2021) · cites this paper as [44]
Experimental — accuracy not yet measured
43 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32661-1 · Cited by 4,616
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,406
Self-citationRNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationFolegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31604-4 · Cited by 2,419
The COVID-19 vaccine development landscape
Thanh Le, T., Andreadakis, Z., Kumar, A., Gómez Román, R., Tollefsen, S., Saville, M., & Mayhew, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/d41573-020-00073-5 · Cited by 1,954
Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis
Osterholm, M. T., Kelley, N. S., Sommer, A., & Belongia, E. A. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70295-x · Cited by 1,789
SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness
Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., et al. (2020) · Nature · doi:10.1038/s41586-020-2622-0 · Cited by 1,615
Self-citationDeveloping Covid-19 Vaccines at Pandemic Speed
Lurie, N., Saville, M., Hatchett, R., & Halton, J. (2020) · New England Journal of Medicine · doi:10.1056/nejmp2005630 · Cited by 1,557
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
Anderson, E. J., Rouphael, N. G., Widge, A. T., Jackson, L. A., Roberts, P. C., Makhene, M., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2028436 · Cited by 1,523
Self-citation
Cited by
Items 3,101–3,200 of 10,906
Qin, Y., Walters, A. A., Rouatbi, N., Wang, J. T.-W., Abdel‐Bar, H. M., & Al‐Jamal, K. T. (2023) · Biomaterials · doi:10.1016/j.biomaterials.2023.122158 · Cited by 28
Zhou, P.-P., Song, G., He, W.-T., Beutler, N., Tse, L.-P. V., Martinez, D. R., Schäfer, A., Anzanello, F., Yong, P., Peng, L., et al. (2022) · bioRxiv · doi:10.1101/2022.03.04.479488 · Cited by 13
Microfluidics for Formulation and Scale-Up Production of Nanoparticles for Biopharma Industry
Yu, M., Mathew, A., Liu, D., Chen, Y., Wu, J., Zhang, Y., & Zhang, N. (2024) · AAPS introductions in the pharmaceutical sciences · doi:10.1007/978-3-031-60717-2_16 · Cited by 43
Disanto, G., Galante, A., Cantù, M., Sacco, R., Mele, F., Eisler, J. J., Keller, F., Bernasconi, E., Sallusto, F., Zecca, C., et al. (2022) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000200043 · Cited by 22
Predictors of COVID-19 Vaccine Uptake in Healthcare Workers: A Cross-Sectional Study in Greece
Galanis, P., Moisoglou, I., Vraka, I. S., Siskou, O. C., Konstantakopoulou, O., Katsiroumpa, A., & Καϊτελίδου, Δ. (2021) · Journal of Occupational and Environmental Medicine · doi:10.1097/jom.0000000000002463 · Cited by 25
Relating In Vitro Neutralization Level and Protection in the CVnCoV (CUREVAC) Trial
Cromer, D., Reynaldi, A., Steain, M., Triccas, J. A., Davenport, M. P., & Khoury, D. S. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac075 · Cited by 23
Buchwinkler, L., Solagna, C. A., Messner, J., Pirklbauer, M., Rudnicki, M., Mayer, G. J., & Kerschbaum, J. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm11010148 · Cited by 31
Simpson, C. R., Kerr, S., Katikireddi, S. V., McCowan, C., Ritchie, L. D., Pan, J., Stock, S. J., Rudan, I., Tsang, R. S. M., de Lusignan, S., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32264-6 · Cited by 24
Konstantinides, S. (2021) · European Respiratory Journal · doi:10.1183/13993003.01111-2021 · Cited by 25
Lakhlifi, C., Lejeune, F., Rouault, M., Khamassi, M., & Rohaut, B. (2023) · Cognitive Research Principles and Implications · doi:10.1186/s41235-023-00474-1 · Cited by 33
Sex-Differential and Non-specific Effects of Vaccines Over the Life Course
Clair, L. A. S., Chaulagain, S., Klein, S. L., Benn, C. S., & Flanagan, K. L. (2023) · Current topics in microbiology and immunology · doi:10.1007/978-3-031-35139-6_9 · Cited by 39
Beeraka, N. M., Sukocheva, O. A., Lukina, E., Liu, J., & Fan, R. (2022) · Reviews in Medical Virology · doi:10.1002/rmv.2346 · Cited by 23
Raw, R. K., Rees, J. C., Kelly, C. A., Wroe, C., & Chadwick, D. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.11.090 · Cited by 24
Impaired Humoral Immunity to SARS-CoV-2 Vaccination in Non-Hodgkin Lymphoma and CLL PatientsPreprint
Diefenbach, C., Caro, J., Koide, A., Grossbard, M. L., Goldberg, J. D., Raphael, B. G., Hymes, K. B., Moskovits, T., Kreditor, M., Kaminetzky, D., et al. (2021) · medRxiv · doi:10.1101/2021.06.02.21257804 · Cited by 26
Forsgård, R. A., Rode, J., Lobenius-Palmér, K., Kamm, A., Patil, S., Tacken, M. G. J., Lentjes, M. A. H., Axelsson, J., Grompone, G., Montgomery, S., et al. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2229938 · Cited by 25
Karbiener, M., Farcet, M. R., Zollner, A., Masuda, T., Mori, M., Moschen, A. R., & Kreil, T. R. (2022) · npj Vaccines · doi:10.1038/s41541-022-00455-3 · Cited by 20
Beyond simple tails: poly(A) tail-mediated RNA epigenetic regulation
Liu, J., & Lu, F. (2024) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2024.06.013 · Cited by 26
Hendricks, G. G., Grigoryan, L., Navarro, M. J., Catanzaro, N., Hubbard, M. L., Powers, J. M., Mattocks, M. D., Treichel, C., Walls, A. C., Lee, J., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adu2085 · Cited by 28
Intranasal mRNA-LNP vaccination protects hamsters from SARS-CoV-2 infectionPreprint
Vaca, G. B., Meyer, M., Cadete, A., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.01.11.523616 · Cited by 23
Nussbaum, J. C., Cao, X., Railkar, R. A., Sachs, J. R., Spellman, D. S., Luk, J. A. M., Shaw, C. A., Cejas, P. J., Citron, M. P., Al-Ibrahim, M. S., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.05.062 · Cited by 24
Zhugunissov, K. D., Zakarya, K. D., Khairullin, B. M., Orynbayev, M. B., Abduraimov, Y. O., Kassenov, M. M., Sultankulova, K. T., Kerimbayev, A. A., Nurabayev, S. S., Myrzakhmetova, B. S., et al. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.720437 · Cited by 27
Racine‐Brzostek, S., Yee, J. K., Sukhu, A. C., Qiu, Y., Rand, S., Barone, P. D., Hao, Y., Yang, H. S., Meng, Q. H., Apple, F. S., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.151477 · Cited by 25
Moeed, A., Najeeb, H., Saleem, A., Asghar, M. S., Rafi, H. M., Khattak, A. K., Bilal, Z., & Seboka, B. T. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.911518 · Cited by 25
Borgoyakova, M. B., Карпенко, Л. И., Рудометов, А. П., Васильевич, Ш. Д., Исаева, А. А., Nesmeyanova, V. S., Волкова, Н. В., Belenkaya, S. V., Murashkin, D. E., Щербаков, Д. Н., et al. (2021) · Molecular Biology · doi:10.1134/s0026893321050046 · Cited by 25
SARS-CoV-2 and COVID-19: A Narrative Review
Blann, A. D., & Heitmar, R. (2022) · British Journal of Biomedical Science · doi:10.3389/bjbs.2022.10426 · Cited by 27
Emmelot, M. E., Vos, M. W., Boer, M. C., Rots, N. Y., de Wit, J., van Els, C. A. C. M., & Kaaijk, P. (2022) · Viruses · doi:10.3390/v14071570 · Cited by 24
ALMuhizi, F., Ton-Leclerc, S., Fein, M. N., et al. (2022) · Frontiers in Allergy · doi:10.3389/falgy.2022.825164 · Cited by 23
One-Stop Serum Assay Identifies COVID-19 Disease Severity and Vaccination Responses
Haddad, N. S., Nguyen, D. C., Kuruvilla, M. E., Morrison-Porter, A., Anam, F. A., Cashman, K. S., Ramonell, R. P., Kyu, S. Y., Saini, A. S., Cabrera-Mora, M., et al. (2021) · ImmunoHorizons · doi:10.4049/immunohorizons.2100011 · Cited by 29
Lu, M., Zhang, Y., Dravid, P., Li, A., Zeng, C., Mahesh, K. C., Trivedi, S., Sharma, H., Chaiwatpongsakorn, S., Zani, A., et al. (2021) · Journal of Virology · doi:10.1128/jvi.00592-21 · Cited by 23
Engineered Nanomaterials for Immunomodulation: A Review
Singh, R., Kumawat, M., Gogoi, H., Madhyastha, H., Lichtfouse, É., & Daima, H. K. (2024) · ACS Applied Bio Materials · doi:10.1021/acsabm.3c00940 · Cited by 25
Elkhalifa, D. H., Rayan, M., Negmeldin, A. T., Elhissi, A. M. A., & Khalil, A. A. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112385 · Cited by 24
mRNA-1273 Vaccine-elicited Neutralization of SARS-CoV-2 Omicron in Adolescents and Children
Girard, B., Tomassini, J. E., Deng, W., Maglinao, M., Zhou, H., Figueroa, A., Ghamloush, S. S., Montefiori, D. C., Das, R., & Pajon, R. (2022) · doi:10.1101/2022.01.24.22269666 · Cited by 23
Self-citationCOVID-19 Vaccination for Endocrine Patients: A Position Statement from the Korean Endocrine Society
Ku, C. R., Jung, K. Y., Ahn, C. H., Moon, J. S., Lee, J. H., Kim, E. H., Kwon, H., Kim, H. K., Suh, S., Hong, S., et al. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2021.404 · Cited by 23
Power in Numbers: Harnessing Combinatorial and Integrated Screens to Advance Nanomedicine
Boehnke, N., & Hammond, P. T. (2021) · JACS Au · doi:10.1021/jacsau.1c00313 · Cited by 22
Demmer, R. T., Baumgartner, B., Wiggen, T. D., et al. (2021) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2022.02.002 · Cited by 23
Li, W.-W., Chen, Y.-Z., Prévost, J., et al. (2021) · bioRxiv · doi:10.1101/2021.08.02.454546 · Cited by 64
COVID-19 Vaccines in Pakistan: Efficacy, Adverse Effects and Availability
Siddique, S., & Ahmed, S. (2021) · Journal of Islamabad Medical & Dental College · doi:10.35787/jimdc.v10i2.723 · Cited by 33
Assessing the impact of mRNA vaccination in chronic inflammatory murine model
Lee, S., Lee, J., Cho, S., Roh, G., Park, H., Lee, Y.-J., Jeon, H.-E., Lee, Y., Bae, S., Youn, S. B., et al. (2024) · npj Vaccines · doi:10.1038/s41541-024-00825-z · Cited by 27
Tan, W. C., Tan, J. Y. J., Lim, J. S. J., Tan, R. S. Y. C., Lee, A. R. Y. B., Leong, F. L., Lee, S. C., Chai, L. Y. A., Tan, T. T., Malek, M. I. B. A., et al. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2023.2271 · Cited by 26
Smith, A. P., Williams, E. P., Plunkett, T. R., Selvaraj, M., Lane, L. C., Zalduondo, L., Xue, Y., Vogel, P., Channappanavar, R., Jonsson, C. B., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.894534 · Cited by 30
Reynolds, L., Dewey, C. E., Asfour, G., & Little, M. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1229716 · Cited by 26
Sacchi, M. C., Pelazza, C., Bertolotti, M., Agatea, L., Gaspari, P. D., Tamiazzo, S., Ielo, D., Stobbione, P., Grappiolo, M., Bolgeo, T., et al. (2023) · Autoimmunity · doi:10.1080/08916934.2023.2229072 · Cited by 24
Allergic Reactions After the Administration of COVID-19 Vaccines
Bian, S., Li, L., Wang, Z., Cui, L., Xu, Y., Guan, K., & Zhao, B. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.878081 · Cited by 25
Protection from COVID-19 with a VSV-based vaccine expressing the spike and nucleocapsid proteins
O’Donnell, K. L., Gourdine, T., Fletcher, P., Clancy, C. S., & Marzi, A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1025500 · Cited by 24
Uaprasert, N., Panrong, K., Rojnuckarin, P., & Chiasakul, T. (2021) · Thrombosis Journal · doi:10.1186/s12959-021-00340-4 · Cited by 25
Debbag, R., Rudin, D., Ceddia, F., & Watkins, J. (2024) · Infectious Diseases and Therapy · doi:10.1007/s40121-024-01079-x · Cited by 32
The influence of interval between doses on response to vaccines
Rodrigues, C. M. C., & Plotkin, S. A. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.10.050 · Cited by 27
COVID-19 pandemic: the delta variant, T-cell responses, and the efficacy of developing vaccines
Biswas, B. K., Chattopadhyay, S., Hazra, S., Hansda, A. K., & Goswami, R. (2022) · Inflammation Research · doi:10.1007/s00011-022-01555-5 · Cited by 27
Hunagund, S., Golan, Y., Asiodu, I. V., Prahl, M. K., & Gaw, S. L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.910383 · Cited by 30
Acute kidney injury after COVID-19 vaccines: a real-world study
Luo, H., Li, X., Ren, Q., Zhou, Y., Chen, G., Zhao, B., & Li, X. (2022) · Renal Failure · doi:10.1080/0886022x.2022.2081180 · Cited by 24
Clinical advancements in mRNA vaccines against viral infections
Fatima, M. T., Park, P., & Hong, K. (2024) · Clinical Immunology · doi:10.1016/j.clim.2024.110424 · Cited by 29
Paoletti, G., Racca, F., Piona, A., Melone, G., Merigo, M., Puggioni, F., Ferri, S., Azzolini, E., Lagioia, M., Lamacchia, D., et al. (2021) · World Allergy Organization Journal · doi:10.1016/j.waojou.2021.100541 · Cited by 23
Marchand, G. J., Masoud, A. T., & Medi, S. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2230828 · Cited by 23
RetractedHuang, L., Zhao, F., He, M., Fang, Y., Ma, X., Lu, S., Li, E., Xiao, H. Q., Zhu, H., Wang, X., et al. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.01.002 · Cited by 24
Recent Developments in SARS-CoV-2 Neutralizing Antibody Detection Methods
Ndzouboukou, J. B., Zhang, Y., & Fan, X. (2021) · Current Medical Science · doi:10.1007/s11596-021-2470-7 · Cited by 24
COVID-19 Vaccine in the Kingdom of Saudi Arabia: A True Operation Warp Speed
Barry, M. A., & BaHammam, A. S. (2021) · Journal of Nature and Science of Medicine · doi:10.4103/jnsm.jnsm_8_21 · Cited by 29
Jiang, F., Zhao, Y. C., Bai, J., Yang, X., Zhang, J., Lin, D., & Li, X. (2022) · PLoS ONE · doi:10.1371/journal.pone.0273285 · Cited by 26
Lipid nanoparticle screening in nonhuman primates with minimal loss of life
Zenhausern, R., Jang, B., Echeverri, E. S., Gentry, K., Calkins, R., Curran, E. H., Wood, J., Stammen, R. L., Loughrey, D., Chappa, P., et al. (2025) · Nature Biotechnology · doi:10.1038/s41587-025-02711-y · Cited by 39
“As all three FDA-approved LNP-RNA drugs use nanoparticles with four components and no targeting ligands 1–3 , we designed 72 chemically distinct LNPs with these criteria (Fig.”
Modified mRNA Therapeutics for Heart Diseases
Magadum, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232415514 · Cited by 26
Underwood, A. P., Sølund, C. S., Fernandez-Antunez, C., Villadsen, S. L., Mikkelsen, L. S., Fahnøe, U., Bollerup, S., Winckelmann, A. A., Schneider, U. V., Binderup, A., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104475 · Cited by 23
Yendewa, G. A., Perez, J. A., Patil, N. T., & McComsey, G. A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1297195 · Cited by 29
Graninger, M., Stumpf, J., Bond, G., Görzer, I., Springer, D. N., Kessel, F., Kröger, H., Frank, K., Tonn, T., Hugo, C., et al. (2023) · Journal of Clinical Virology · doi:10.1016/j.jcv.2023.105428 · Cited by 26
Specificity of pharmacokinetic modeling of nanomedicines
Lebreton, V., Legeay, S., Saulnier, P., & Lagarce, F. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.04.017 · Cited by 27
SARS-CoV-2 Vaccination and Neuroimmunological Disease: A Review
Willison, A., Pawlitzki, M., Lunn, M. P., Willison, H. J., Hartung, H., & Meuth, S. G. (2024) · JAMA Neurology · doi:10.1001/jamaneurol.2023.5208 · Cited by 26
Seroresponse to SARS-CoV-2 Vaccines Among Maintenance Dialysis Patients
Hsu, C. M., Weiner, D. E., Aweh, G. N., Manley, H. J., Ladik, V., Frament, J. M., Miskulin, D. C., Argyropoulos, C., Abreo, K. D., Chin, A. I., et al. (2021) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2021.10.002 · Cited by 24
Nonclinical safety evaluation of a novel ionizable lipid for mRNA delivery
Broudic, K., Amberg, A., Schaefer, M. K., Spirkl, H.-P., Bernard, M., & Désert, P. (2022) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2022.116143 · Cited by 26
Curvature effects in charge-regulated lipid bilayers
Khunpetch, P., Majee, A., & Podgornik, R. (2022) · Soft Matter · doi:10.1039/d1sm01665b · Cited by 23
Deng, J., Fukushima, Y., Nozaki, K., Nakanishi, H., Yada, E., Terai, Y., Fueki, K., & Itaka, K. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091785 · Cited by 29
Painter, M. M., Mathew, D., Goel, R. R., Apostolidis, S. A., Pattekar, A., Kuthuru, O., Baxter, A. E., Herati, R. S., Oldridge, D. A., Gouma, S., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.04.21.440862 · Cited by 22
Immunogenicity of SARS-CoV-2 vaccines in patients with cancer
Kakkassery, H., Carpenter, E., Patten, P., & Irshad, S. (2022) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2022.07.006 · Cited by 24
Development of COVID-19 vaccine policy — United States, 2020–2023
Oliver, S. E., Wallace, M. M., Twentyman, E., Moulia, D., Godfrey, M., Link‐Gelles, R., Meyer, S. A., Fleming-Dutra, K. E., Hall, E., Wolicki, J., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.12.022 · Cited by 27
Kerr, J. R., Freeman, A. L. J., Marteau, T. M., et al. (2021) · medRxiv · doi:10.1101/2021.03.19.21253963 · Cited by 22
Dickens, B. S. L., Koo, J. R., Lim, J. T., et al. (2021) · Journal of Travel Medicine · doi:10.1093/jtm/taab088 · Cited by 22
Florea, A., Sy, L. S., Luo, Y., Qian, L., Bruxvoort, K. J., Ackerson, B. K., Lee, G. S., Ku, J. H., Tubert, J. E., Tian, Y., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0267824 · Cited by 21
Liu, W., Zhang, M., Lv, H., & Yang, C. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17080950 · Cited by 28
“Notably, the LNP formulations used in the Pfizer-BioNTech (BNT162b2) and Moderna (mRNA-1273) COVID-19 vaccines were approved by both the U.S. FDA and the European Medicines Agency (EMA) in 2020, marking a major milestone in the field [7,8].”
SARS-CoV-2 infection and immune responses
Harne, R., Williams, B., Abdelaal, H. F. M., Baldwin, S. L., & Coler, R. N. (2023) · AIMS Microbiology · doi:10.3934/microbiol.2023015 · Cited by 24
Clairon, Q., Prague, M., Planas, D., Bruel, T., Hocqueloux, L., Prazuck, T., Schwartz, O., Thiébaut, R., & Guedj, J. (2023) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1011282 · Cited by 29
Toniutto, P., Cussigh, A., Cmet, S., Bitetto, D., Fornasiere, E., Fumolo, E., Fabris, M., D’Aurizio, F., Fabris, C., Grillone, L., et al. (2022) · Liver International · doi:10.1111/liv.15331 · Cited by 22
A Virion-Based Combination Vaccine Protects against Influenza and SARS-CoV-2 Disease in Mice
Chaparian, R. R., Harding, A. T., Hamele, C. E., Riebe, K. J., Karlsson, A., Sempowski, G. D., Heaton, N. S., & Heaton, B. E. (2022) · Journal of Virology · doi:10.1128/jvi.00689-22 · Cited by 26
Dalwadi, V., Hancock, D., Ballout, A. A., & Geraci, A. P. (2021) · Cureus · doi:10.7759/cureus.18291 · Cited by 23
N2 modified dinucleotide cap analogs as a potent tool for mRNA engineering
Grzela, R., Piecyk, K., Stankiewicz-Drogoń, A., Pietrow, P., Łukaszewicz, M., Kurpiejewski, K., Darżynkiewicz, E., & Jankowska‐Anyszka, M. (2022) · RNA · doi:10.1261/rna.079460.122 · Cited by 23
Dynamic Interactions of Fully Glycosylated SARS-CoV-2 Spike Protein with Various Antibodies
Cao, Y., Choi, Y. K., Frank, M., Woo, H., Park, S., Yeom, M. S., Seok, C., & Im, W. (2021) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.1c00552 · Cited by 24
Erra, L., Uriarte, I. L., Colado, A., Paolini, M. V., Seminario, G. A., Fernández, J. B., Tau, L., Bernatowiez, J., Moreira, I., Vishnopolska, S. A., et al. (2022) · Journal of Clinical Immunology · doi:10.1007/s10875-022-01382-7 · Cited by 24
Modeling the Impact of COVID-19 Vaccination in Lebanon: A Call to Speed-Up Vaccine Roll Out
Mumtaz, G. R., El‐Jardali, F., Jabbour, M., Harb, A., Abu-Raddad, L. J., & Makhoul, M. (2021) · Vaccines · doi:10.3390/vaccines9070697 · Cited by 25
Otero-Losada, M., Petrovsky, N., Alami, A., Crispo, J. A., Mattison, D., Capani, F., Goetz, C., Krewski, D., & Perez-Lloret, S. (2023) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2120607 · Cited by 22
Ocular Complications after COVID-19 Vaccination, Vaccine Adverse Event Reporting System
Nyankerh, C. N. A., Boateng, A. K., & Appah, M. (2022) · Vaccines · doi:10.3390/vaccines10060941 · Cited by 24
Cassidy, A. G., Li, L., Golan, Y., Gay, C., Lin, C. Y., Jigmeddagva, U., Chidboy, M. A., Ilala, M., Buarpung, S., Gonzalez, V. J., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.23405 · Cited by 26
Chua, C. E., Kew, G. S., Demutska, A., Quek, S. X. Z., Loo, E. X. L., Gui, H., Wong, S., Lau, H. X., Low, E. X. S., Loh, T. L., et al. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-046310 · Cited by 26
Kyprianidou, M., Konstantinou, P., Álvarez‐Gálvez, J., Ceccarelli, L., Gruszczyńska, E., Mierzejewska-Floreani, D., Loumba, N., Montagni, I., Tavoschi, L., Karekla, M., et al. (2022) · Behavioral Medicine · doi:10.1080/08964289.2022.2071198 · Cited by 22
Doherty, J., Morain, N. O., Stack, R., Girod, P., Tosetto, M., Inzitiari, R., Sheridan, J., Cullen, G. J., McDermott, E., Buckley, M., et al. (2022) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjac029 · Cited by 25
Barghash, R. F., Gemmati, D., Awad, A. M., Elbakry, M. M. M., Tisato, V., Awad, K., & Singh, A. V. (2024) · Molecules · doi:10.3390/molecules29235564 · Cited by 27
Advances in the study of LNPs for mRNA delivery and clinical applications
Wang, B., Shen, B., Xiang, W., & Shen, H. (2024) · Virus Genes · doi:10.1007/s11262-024-02102-6 · Cited by 22
Efficacy of COVID-19 vaccines by race and ethnicity
Salari, N., Vepa, A., Daneshkhah, A., Darvishi, N., Ghasemi, H., Khunti, K., & Mohammadi, M. (2022) · Public Health · doi:10.1016/j.puhe.2022.04.009 · Cited by 24
Carnell, G., Billmeier, M., Vishwanath, S., Sans, M. S., Wein, H., George, C. L., Neckermann, P., Rosario, J. M. M. D., Sampson, A., Einhauser, S., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1118523 · Cited by 23
Kotaki, R., Moriyama, S., Oishi, S., Onodera, T., Adachi, Y., Sasaki, E., Ishino, K., Morikawa, M., Takei, H., Takahashi, H., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adp9927 · Cited by 29
SARS-CoV-2 (COVID-19) Variants and COVID-19 Vaccine Efficacy
Cheepsattayakorn, A. (2021) · Open Access Journal of Pulmonary & Respiratory Sciences · doi:10.23880/oajprs-16000135 · Cited by 21
Will Host Genetics Affect the Response to SARS-CoV-2 Vaccines? Historical Precedents
Smatti, M. K., Al-Khatib, H. A., Thani, A. A. A., & Yassine, H. M. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.802312 · Cited by 28
Kantarcıoğlu, B., Iqbal, O., Lewis, J., Carter, C. A., Singh, M., Lievano, F. A., Ligocki, M. A., Jeske, W. P., Adıgüzel, C., Gerotziafas, G., et al. (2022) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/10760296211056648 · Cited by 26
Overview of approved and upcoming vaccines for SARS-CoV-2: a living review
Alderson, J., Batchelor, V., O’Hanlon, M., Cifuentes, L., Richter, F. C., & Kopycinski, J. T. (2021) · Oxford Open Immunology · doi:10.1093/oxfimm/iqab010 · Cited by 22
Advancing mRNA Therapeutics: The Role and Future of Nanoparticle Delivery Systems
Li, J., Zhang, Y., Yang, Y., & Sun, T. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00276 · Cited by 26
Metadata
- Authors
- Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., McGettigan, J., Khetan, S., Segall, N., Solis, J., Brosz, A., Fierro, C., Schwartz, H., Neuzil, K., Corey, L., Gilbert, P., Janes, H., Follmann, D., Marovich, M., Mascola, J., Polakowski, L., Ledgerwood, J., Graham, B. S., Bennett, H., Pajon, R., Knightly, C., Leav, B., Deng, W., Zhou, H., Han, S., Ivarsson, M., Miller, J., & Zaks, T.
- Affiliations
- Brigham and Women's Hospital (US)
- From Brigham and Women’s Hospital (L.R.B.), Boston, and Moderna, Cambridge (H.B., R.P., C.K., B.L., W.D., H.Z., S.H., M.I., J. Miller, T.Z.) — both in Massachusetts; Baylor College of Medicine (H.M.E.S.) and Centex Studies (J.S.) — both in Houston; Meridian Clinical Research, Savannah (B.E., S.K., A.B.), and Emory University (N.R.) and Atlanta Clinical Research Center (N.S.), Atlanta — all in Georgia; University of Maryland School of Medicine, Baltimore (K.K., K.N.), and National Institute of Allergy and Infectious Diseases, Bethesda (D.F., M.M., J. Mascola, L.P., J.L., B.S.G.) — both in Maryland; Saint Louis University School of Medicine, St. Louis (S.F.); University of Illinois, Chicago, Chicago (R.N.); George Washington University School of Medicine and Health Sciences, Washington, DC (D.D.); University of California, San Diego, San Diego (S.A.S.); Vanderbilt University School of Medicine, Nashville (C.B.C.); Quality of Life Medical and Research Center, Tucson, AZ (J. McGettigan); Johnson County Clin-Tr...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-02-04
- Volume
- 384
- Issue
- 5
- Pages
- 403-416
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7787219
- OpenAlex
- W3113734454
- Cited by
- 10,119
- References
- 24
- Citations by year
- 2026: 622 · 2025: 962 · 2024: 1186 · 2023: 1691 · 2022: 2854 · 2021: 2793
- FWCI
- 240.84
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- New England Journal of Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (ACTG Leadership and Operations Center UM1 AI 68636, HPTN Leadership and Operations Center UM1 AI 68619, HVTN Laboratory Center UM1 AI 68618, HVTN Leadership and Operations Center UM1 AI 68614, HVTN Statistics and Data Management Center UM1 AI, IDCRC leadership group 5 UM1 AI148684-03)
- Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (Contract No. 75A50120C00034)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- mRNA-1273 vaccine, SARS-CoV-2, COVID-19 vaccines, vaccine efficacy, vaccine safety, reactogenicity, adverse events, vulnerable populations, older adults, immunocompromised patients, breakthrough infection, severe COVID-19 prevention
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, 2019-nCoV Vaccine mRNA-1273, Adolescent, Adult, Aged, Female, Humans, Male, Middle Aged, Incidence, Single-Blind Method, Treatment Outcome, Young Adult, Patient Acuity, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.